Email:
Phone:

Get A Quote

Inquiry

Lipid-Drug Conjugation

Name: Lipid-Drug Conjugation
Brand: BOC Sciences

Lipid-drug conjugates (LDCs) refers to the chemical linkage of drug molecules with lipid molecules, forming complexes with specific pharmacokinetic and biodistribution properties. The lipid component can be fatty acids, phospholipids, cholesterol, or triglycerides, while the drug component is typically small-molecule chemotherapeutics, anti-infective agents, or bioactive molecules. Lipid-drug conjugation can significantly enhance drug solubility, membrane permeability, and in vivo stability. By selecting an appropriate linker, such as ester, amide, disulfide, or pH-sensitive chemical bonds, targeted and controlled drug release can be achieved. BOC Sciences leverages its expert team, diverse lipid portfolio, and advanced chemical synthesis technologies to provide end-to-end solutions, including design, synthesis, analysis, modification, and conjugation. Our services not only improve in vivo performance but also help clients optimize pharmacokinetics and therapeutic outcomes in the early stages of drug development.

Advanced Lipid-Drug Conjugation Services

BOC Sciences offers professional lipid-drug conjugates aimed at enhancing drug solubility, stability, and targeting through chemical modification. Our services cover lipid selection, drug conjugation, linker design, and customized solutions to support efficient and safe drug delivery.

Lipid Carriers
Fatty Acids: Improve membrane permeability and in vivo distribution of hydrophobic drugs.
Phospholipids: Used to construct liposomes or nanoparticles, enhancing drug loading and circulation stability.
Cholesterol Derivatives: Strengthen lipid particle stability and prolong blood half-life.
Triglycerides: Suitable for highly hydrophobic drugs, improving solubility and delivery efficiency.
Drug Molecules
Small-Molecule Chemotherapeutics: Conjugation improves targeting and therapeutic effect.
Anti-Infective Agents: Enhances plasma stability and tissue distribution.
Bioactive Molecules: Maintains activity while enabling controlled release.
Multi-Drug Combinations: Supports co-conjugation strategies to enhance synergistic efficacy.
Highly Controllable Linker Design
Ester Bonds: Suitable for enzyme-sensitive release; drugs are released via in vivo esterases.
Amide Bonds: High stability, ideal for drugs requiring slow release.
Disulfide Bonds: Triggered release in reductive environments (e.g., inside tumor cells).
pH-Sensitive Linkers: Degrade in acidic microenvironments for targeted release.
Customized Services
End-to-End Customization: One-stop service from design, synthesis, purification to analytical validation.
Conjugation Efficiency Assessment: Provides drug loading, conjugation efficiency, and in vitro release data.
Process Optimization: Supports small-scale R&D, pilot, and industrial production.
Technical Support: Offers tailored technical solutions and professional consultation based on client needs.

Interested in Our Lipid Conjugation Services?

Get in touch with our experts today! We'll respond within 24 hours to discuss your project needs and provide a customized quote.

Submit Your Request Now

Supported Lipid-Drug Conjugates by BOC Sciences

With a rich lipid library and advanced chemical synthesis technologies, BOC Sciences supports various types of lipid-drug conjugates, including fatty acids, phospholipids, cholesterol, triglycerides, sphingolipids, polymeric lipids, and functionalized lipid conjugates. Each type has unique chemical structures and biological properties, enabling customized design according to the physicochemical properties of drugs and clinical application requirements. These diverse conjugation strategies allow clients to achieve higher efficiency, more precise targeting, and optimized in vivo pharmacokinetics during drug development.

Fatty Acid-Drug Conjugates Drugs are directly conjugated to long-chain fatty acids such as palmitic, oleic, or stearic acid, enhancing hydrophobicity and cell membrane penetration. They can also bind plasma albumin, significantly prolonging in vivo half-life and circulation stability.
Phospholipid-Drug Conjugates Conjugating drugs with phospholipids like PC or PG enables spontaneous formation of liposomes or micelles in aqueous solutions, achieving efficient drug encapsulation and delivery. Some phospholipids also have intrinsic bioactivity, working synergistically to improve therapeutic outcomes.
Cholesterol-Drug Conjugates Drugs linked to cholesterol or its derivatives enhance liposome stability and membrane penetration. Suitable for nucleic acid delivery (e.g., siRNA, ASO), they enable efficient receptor-mediated targeted cellular uptake.
Triglyceride-Drug Conjugates Drugs attached to a glycerol backbone mimic triglyceride structures and can form lipid nanoparticles (LNPs), achieving efficient encapsulation and delivery, while improving hydrophobic drug stability and bioavailability.
Lipid-Small Molecule Drug Conjugates Mainly conjugates of chemotherapeutics like paclitaxel and camptothecin derivatives. Lipid conjugation improves solubility and pharmacokinetics, reduces systemic toxicity, enhances therapeutic index, and supports precise targeted delivery.
Lipid-Nucleic Acid Conjugates Lipid conjugation with siRNA, mRNA, or ASO significantly improves in vivo stability and cellular delivery efficiency, a key technology for gene therapy, rare disease treatment, and vaccine development.
Lipid-Peptide or Protein Conjugates Conjugating lipids to therapeutic peptides or small proteins extends half-life, enhances bioactivity, and increases tissue accumulation for prolonged dosing and targeted therapy.
Lipid Nanoparticles (LNPs) Composed of ionizable lipids, cholesterol, helper lipids, and PEGylated lipids, LNPs efficiently encapsulate nucleic acid drugs. They are the core technology platform for mRNA vaccines and gene therapeutics, offering both stability and targeting capability.

Looking for Custom Lipid-Drug Conjugates?

Whether you need small molecule, nucleic acid, peptide, or protein conjugates, our experts can design and deliver optimized solutions for your project.

Contact Our Lipid Specialists Today!

Strengths of Our Lipid-Drug Conjugation Solutions

Extensive Lipid Library and Diverse Conjugation Strategies: We offer a wide range of lipid types, including fatty acids, phospholipids, cholesterol, triglycerides, and functionalized lipids. By combining chemical conjugation, enzymatic catalysis, or controllable linker design, we provide versatile conjugation solutions to meet different drug delivery requirements.
Highly Controllable Conjugation Efficiency and Drug Loading: Optimized synthesis conditions and strict quality control ensure that drug loading and conjugation efficiency meet design specifications, providing reliable data support for subsequent formulation development and performance optimization.
End-to-End Customized Services: Our services cover the complete workflow, from needs analysis, molecular design, chemical synthesis, purification, and characterization to nanoparticle preparation and functional evaluation. This one-stop solution reduces client R&D timelines and operational complexity.
High-Quality Standards and Structural Verification: Advanced analytical techniques such as HPLC, mass spectrometry (MS), and nuclear magnetic resonance (NMR) are employed for rigorous purification and structural confirmation, ensuring chemical purity, correct molecular structure, and reproducibility.
Preclinical and Industrial Application Potential: Our services support flexible scale-up from small-scale R&D and pilot studies to industrial production. Conjugation designs can be optimized according to drug properties and development goals, providing reliable technical support for gene therapy, oncology, and vaccine development.
Professional Technical Support and Customized Solutions: Experienced biochemistry and medicinal chemistry experts provide professional consultation, developing tailored conjugation strategies for different drug properties and research requirements to enhance delivery efficiency and targeting.
Certifications and Compliance: Our production facilities meet cGMP standards, providing products and services aligned with international regulations, supporting subsequent industrialization and regulatory compliance.
Global Delivery Capability: Flexible international logistics and global shipping services are available, supporting delivery of small R&D samples as well as pilot or industrial-scale shipments, ensuring safe and rapid arrival at client laboratories or production sites.

Custom Lipid-Drug Conjugation Service Workflow

Requirements Analysis and Design Based on the client's drug information, physicochemical properties, and development goals, we select appropriate lipid carriers and design linkers, evaluating the suitability of different lipids and conjugation methods. Structure modeling and feasibility analysis are used to propose optimal conjugation strategies, maximizing drug delivery performance and targeting.
Chemical Synthesis and Conjugation Optimized chemical reaction conditions enable efficient conjugation while maintaining drug activity. Depending on drug properties, chemical or enzymatic conjugation can be employed, with flexible reaction systems to improve yield and control, ensuring stable and reproducible conjugate structures.
Conjugate Purification and Characterization Advanced chromatographic techniques (e.g., HPLC), MS, and NMR are used for purification and structural verification, ensuring chemical purity and correct molecular structure. Physical and chemical properties such as solubility and stability are also assessed to provide reliable data for downstream applications.
Drug Loading and Conjugation Efficiency Evaluation Quantitative analysis determines drug loading and conjugation efficiency, assessing whether the conjugation meets design requirements. These data provide precise guidance for nanoparticle preparation or formulation optimization, ensuring controllability during R&D and development.
Nanoparticle Preparation (Optional) If required, lipid-drug conjugates can be assembled into liposomes, LNPs, or microemulsions to enhance in vivo stability and targeted delivery. Particle size, surface modifications, and release profiles can be adjusted to meet various administration routes and therapeutic needs.
Functional Evaluation In vitro solubility testing, drug release kinetics, cellular uptake, and activity assays are performed to verify conjugate functionality and biological effects. These experimental data ensure that the conjugates exhibit optimal drug delivery and therapeutic performance, laying the foundation for preclinical or industrial applications.

Interested in Our Custom Lipid Solutions?

Contact our lipid chemistry experts to discuss your project needs.

Request a Free Consultation

Applications of Lipid-Drug Conjugates

Lipid-drug conjugates play an increasingly important role in modern drug development. By covalently linking drug molecules to lipid carriers, LDCs improve solubility, stability, and in vivo distribution, enabling targeted delivery and controlled release. LDCs are not only suitable for small-molecule chemotherapeutics but are also widely used in nucleic acid, peptide, and protein delivery, as well as in constructing nanoparticle carriers and multifunctional combination therapy platforms. With their advantages of efficient delivery, low toxicity, and precise targeting, lipid-drug conjugates are becoming essential tools in oncology, gene therapy, and vaccine development, providing strong support for new drug development and clinical applications.

Anticancer Drug Delivery Lipid-drug conjugation enhances the solubility and in vivo distribution of chemotherapeutic agents, enabling targeted and controlled release. For example, conjugating paclitaxel or doxorubicin to lipid carriers allows selective accumulation in tumor tissues via the EPR effect, increasing local drug concentration while reducing systemic toxicity, significantly improving the therapeutic index and clinical outcomes.
Nucleic Acid Drug Delivery Lipid conjugation plays a key role in the delivery of siRNA, mRNA, and antisense oligonucleotides (ASOs). Lipid modifications improve in vivo stability, cellular uptake efficiency, and tissue targeting. These conjugates are widely applied in gene therapy, rare disease treatment, and vaccine development, such as mRNA vaccines and gene editing platforms.
Small-Molecule Drug Improvement Lipid conjugation can enhance the water solubility and pharmacokinetic properties of hydrophobic small-molecule drugs. By linking drugs to fatty acids, cholesterol, or phospholipids, in vivo half-life and distribution patterns are optimized, systemic toxicity is reduced, and sustained or long-term formulations can be supported.
Peptide and Protein Drug Enhancement Conjugating lipids to therapeutic peptides or small proteins extends half-life and enhances tissue targeting. For example, GLP-1 receptor agonists, interferons, or antibody fragments can be lipid-modified to allow weekly or longer dosing intervals while maintaining bioactivity and therapeutic stability.
Nanoparticle Delivery System Construction Lipid-drug conjugates can serve as the core components of liposomes, LNPs, or micelles, improving drug encapsulation efficiency and stability. By adjusting lipid structure and surface modifications, controlled release, targeted delivery, and prolonged circulation time can be achieved, widely applied in vaccines, anticancer agents, and nucleic acid drug platforms.
Multifunctional Combination Therapy Lipid-drug conjugation supports combination therapy development by linking different drugs or functional molecules to the same lipid carrier for synergistic treatment. For instance, combining chemotherapeutics with nucleic acids or immune modulators creates multifunctional LDC platforms, enhancing therapeutic efficacy while reducing systemic side effects for precision medicine applications.

Frequently Asked Questions

Still have questions?

What are lipid-drug conjugates?
Lipid-drug conjugates (LDCs) are compounds in which drugs are covalently linked to lipid molecules, improving solubility, stability, and in vivo distribution. LDCs can be optimized by adjusting lipid chain length, saturation, or linker type to control drug release and targeting, enhancing efficacy while minimizing side effects.
What research fields can lipid-drug conjugates be applied to?
LDCs are widely applied in drug delivery, anticancer drug optimization, gene therapy vectors, vaccine development, lipid nanoparticle (LNP) design, and targeted drug development. In drug development, LDCs improve targeting and bioavailability; in industrial applications, they optimize stability and in vivo release. BOC Sciences leverages extensive experience and advanced technologies to support applications from academic research to scale-up production.
What advantages do lipid-drug conjugates have over traditional drugs?
Compared to traditional drugs, LDCs offer significant advantages. They improve water solubility and bioavailability and optimize in vivo distribution. LDCs extend half-life via lipid carriers, reducing frequent dosing requirements. Additionally, lipid conjugation enables targeted release, minimizing off-target toxicity and enhancing safety.
How do lipid-drug conjugates differ from antibody-drug conjugates (ADC)?
Lipid-drug conjugation covalently links drug molecules to specific lipid molecules via chemical linkers. Unlike ADCs, which rely on antibody targeting, LDCs utilize the self-assembly properties of lipids—forming liposomes or nanoparticles in aqueous solutions—to encapsulate and deliver drugs. This provides greater versatility and lower immunogenicity in certain applications, offering a new strategy for drug delivery.
What types of drug molecules can your lipid-drug conjugation service handle?
Our services are highly flexible and can conjugate a wide range of drug molecules, including but not limited to:
- Small-molecule drugs: such as chemotherapeutics and targeted agents.
- Nucleic acid drugs: such as siRNA, mRNA, and oligonucleotides.
- Peptides and proteins: such as short peptides and insulin.
- Other functional molecules: such as fluorescent probes or radiolabels.
Our expert team develops the optimal conjugation strategy for your project, ensuring drug functionality is maintained.
How is the quality of lipid-drug conjugates ensured?
Quality control is central to our service. Throughout the conjugation process, strict quality management is implemented. Advanced analytical tools such as high-resolution mass spectrometry (HRMS), nuclear magnetic resonance (NMR), and high-performance liquid chromatography (HPLC) are used for comprehensive analysis of purity, structure, and stability. Detailed analytical reports are provided, and all products are delivered to meet pre-defined specifications and purity standards, ensuring complete confidence in product quality.

Case Studies and Success Stories

Background

A European research team, while developing a novel anticancer drug delivery system, planned to improve the solubility and targeting of a candidate drug through a lipid–drug conjugation strategy. They selected a hydrophobic small molecule with known antitumor activity, but its rapid metabolism and short plasma half-life in vivo hindered the achievement of the desired therapeutic effect. Therefore, the team decided to conjugate it with a lipid backbone, utilizing a nanoliposome delivery system to achieve controlled drug release.

What Does BOC Sciences Do?

After receiving the request, BOC Sciences first communicated thoroughly with the client to clarify project objectives and challenges, identifying the optimal conjugation site of the small molecule drug and the required lipid backbone type. Based on molecular simulation results, the R&D team designed multiple synthetic routes and selected the optimal one through structural and performance predictions. Ultimately, PEG–phospholipid derivatives were used as a linker to successfully achieve covalent conjugation between the drug and the phospholipid backbone. We provided:

Established a scalable process from milligram to gram scale, ensuring robust conditions suitable for further scale-up;
Confirmed product structure and purity using preparative HPLC, NMR, LC-MS, and other methods;
Systematically evaluated solubility, storage stability, and liposome encapsulation efficiency of the conjugates;
Provided original analytical records and COA reports meeting regulatory requirements, facilitating direct inclusion in client submission files.

Key Outcomes

Successfully obtained high-purity (>98%) lipid–drug conjugates;
The client successfully prepared nanoliposomes, significantly extending in vivo circulation time of the drug;
Animal studies demonstrated approximately two-fold improvement in tumor inhibition with reduced side effects;
The client advanced preclinical studies as planned and gave highly positive feedback on our custom synthesis services.

Background

A North American biotechnology company was developing an oligonucleotide-based gene silencing therapy. Since oligonucleotides inherently have low efficiency in penetrating cell membranes, the research team decided to enhance cellular uptake and in vivo stability by conjugating them with lipids. The project aimed to synthesize a cholesterol-modified oligonucleotide to improve targeted delivery efficiency to the liver.

What Does BOC Sciences Do?

Upon receiving the request, BOC Sciences' expert team evaluated the chemical structure of the target sequence and the feasibility of modification, proposing several lipid conjugation strategies. After validation, cholesterol derivatives were selected as hydrophobic modification groups, and an efficient solid-phase conjugation process was employed to achieve terminal attachment with the oligonucleotide sequence. Throughout the process, the R&D team maintained close communication with the client to ensure alignment of design strategies with project objectives. We provided:

Established an efficient solid-phase conjugation process with low by-products, supporting scalability from small-scale to pilot-scale production;
Verified conjugation efficiency and purity using UPLC, MALDI-TOF MS, PAGE, and other multidimensional techniques;
Conducted in vitro tests for transfection efficiency, serum stability, and cellular uptake to confirm authentic conjugation effects;
Compiled detailed process parameters, analytical methods, and stability reports to support client IND submission.

Key Outcomes

The synthesized cholesterol–oligonucleotide conjugates achieved purity greater than 97%;
In cell experiments, oligonucleotide uptake efficiency increased more than three-fold;
In mouse liver, drug deposition significantly increased with clear gene silencing effects;
The client incorporated these results into subsequent IND submission documents, accelerating R&D progress.

Publications

Our publications section highlights scientific achievements from global clients who have published in high-impact journals using BOC Sciences' lipid products and custom services, demonstrating the reliability and broad application value of our solutions.

Development and validation of rapid and simultaneous method for determination of 12 hair-growth compounds in adulterated products by UHPLC–MS/MS. Forensic science international 284 (2018): 129-135. PMID: 29408720 DOI: 10.1016/j.forsciint.2017.12.042.
Hopanoids, like sterols, modulate dynamics, compaction, phase segregation and permeability of membranes. Biochimica et Biophysica Acta (BBA)-Biomembranes (2019): 183060. DOI: 10.1016/j.bbamem.2019.183060.
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome. Pharmaceutics 14.9 (2022): 1895. PMID: 36145642 DOI: 10.3390/pharmaceutics14091895.
Osteogenic effects of rapamycin on bone marrow mesenchymal stem cells via inducing autophagy. Journal of Orthopaedic Surgery and Research 18.1 (2023): 129. PMID: 36814286 DOI: 10.1186/s13018-023-03616-9.
Liquid chromatography–tandem mass spectrometry method for the analysis of N-(3-aminopropyl)-N-dodecylpropane-1, 3-diamine, a biocidal disinfectant, in dairy products. Food chemistry 262 (2018): 168-177. DOI: 10.1016/j.foodchem.2018.04.080.

More Publications

Client Testimonials

Industry Distribution of Custom Lipid Synthesis Clients

"The conjugates we received were of outstanding purity and fully reproducible across batches. This consistency gave our team great confidence in pushing forward to the next development stage."
— Dr. Michael Turner, Senior Scientist (United States)
"Facing a very short preclinical deadline, we urgently needed lipid–drug conjugates at gram scale. The synthesis was completed on time, with full analytical support, which kept our program on track."
— Ms. Laura Schmidt, Formulation Scientist (Germany)

"In our drug delivery studies, we urgently needed stable conjugates of small molecules with lipids. The BOC Sciences team not only completed the synthesis efficiently but also supplied detailed characterization data, enabling us to move forward with preclinical studies smoothly."
— Ms. Laura Schmidt, Formulation Scientist (Germany)
"What impressed me most was the clear communication throughout the project. Every technical detail was addressed proactively, and the delivered conjugates met our specifications precisely."
— Dr. Andrew Collins, Principal Investigator (United Kingdom)

"We have collaborated with BOC Sciences for years, and they consistently maintain high standards in quality control and communication for custom lipid–drug conjugates. They are a reliable and trusted partner."
— Ms. Sofia Novak, Biotech Project Leader (Sweden)
"We've collaborated on several custom syntheses, and the reliability has been remarkable. From early communication to final delivery, the process was smooth and highly professional."
— Ms. Sofia Novak, Biotech Project Leader (Sweden)

Custom Lipid Conjugation Made Easy — Request A Quote, Available 24/7.